Clinical Trial Update: A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2, single-arm, dose-escalation trial evaluating long-acting recombinant human IL-7 (NT-I7/efineptakin alfa) in idiopathic CD4+ lymphocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Cd4 Lymphocytopenia

Drugs mentioned

• NT-I7 (efineptakin alfa) (efineptakin alfa)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Idiopathic CD4 Lymphopenia | Phase 1, Phase 2 | Status: RECRUITING